Braun Stacey Associates Inc. lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 6.8% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 225,780 shares of the company’s stock after selling 16,525 shares during the period. Braun Stacey Associates Inc.’s holdings in Zoetis were worth $14,396,000 at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in the company. CGOV Asset Management lifted its stake in shares of Zoetis by 2.7% during the first quarter. CGOV Asset Management now owns 169,605 shares of the company’s stock valued at $12,059,000 after acquiring an additional 4,405 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Zoetis by 3.5% during the first quarter. Dimensional Fund Advisors LP now owns 1,303,869 shares of the company’s stock valued at $69,587,000 after acquiring an additional 43,896 shares during the period. Morgan Stanley lifted its stake in shares of Zoetis by 182.5% during the first quarter. Morgan Stanley now owns 14,617,205 shares of the company’s stock valued at $780,119,000 after acquiring an additional 9,442,207 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Zoetis by 31.6% during the first quarter. Renaissance Technologies LLC now owns 1,131,700 shares of the company’s stock valued at $60,399,000 after acquiring an additional 271,700 shares during the period. Finally, BlackRock Inc. lifted its stake in shares of Zoetis by 2,471.1% during the first quarter. BlackRock Inc. now owns 36,082,470 shares of the company’s stock valued at $1,925,722,000 after acquiring an additional 34,679,064 shares during the period. Institutional investors own 92.90% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/11/12/zoetis-inc-zts-shares-sold-by-braun-stacey-associates-inc.html.
Shares of Zoetis Inc. (ZTS) opened at $69.13 on Friday. Zoetis Inc. has a 52-week low of $48.24 and a 52-week high of $70.48. The stock has a market capitalization of $33,769.08, a P/E ratio of 31.79, a PEG ratio of 2.03 and a beta of 1.02. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.02. The company had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.32 billion. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The business’s revenue was up 8.5% on a year-over-year basis. During the same period last year, the firm posted $0.52 earnings per share. sell-side analysts anticipate that Zoetis Inc. will post 2.36 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be issued a dividend of $0.105 per share. The ex-dividend date is Wednesday, November 8th. This represents a $0.42 annualized dividend and a yield of 0.61%. Zoetis’s payout ratio is currently 22.11%.
ZTS has been the topic of several analyst reports. Cowen and Company set a $70.00 target price on Zoetis and gave the company a “buy” rating in a research note on Monday, July 17th. Cantor Fitzgerald set a $75.00 target price on Zoetis and gave the company a “buy” rating in a research note on Monday, August 14th. Stifel Nicolaus reissued a “buy” rating and issued a $65.00 target price on shares of Zoetis in a research note on Friday, July 21st. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $62.00 target price on shares of Zoetis in a research note on Monday, August 7th. Finally, BMO Capital Markets increased their price target on Zoetis from $65.00 to $70.00 and gave the stock a “market perform” rating in a report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $67.06.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.